Legend Biotech Corp (NASDAQ:LEGN)
| Market Cap | $2.82B-43.8% |
| Revenue (ttm) | $1.36B+49.5% |
| Net Income | -$215.00K+99.9% |
| EPS | $0.00+97.7% |
| Shares Out | 184.94M |
| PE Ratio | n/a |
| Forward PE | 31.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,422,884 |
| Open | $15.95 |
| Previous Close | $16.10 |
| Day's Range | $15.14 - $16.11 |
| 52-Week Range | $15.14 - $37.50 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | $61.00(+300.00%) |
| Earnings Date | Mar 9, 2027 |
About LEGN
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corp Stock Analysis — InsiderScore
Legend Biotech Corp scored higher than 74% of companies evaluated by InsiderBuying, and ranked 25th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Legend Biotech Corp bought $183.3K of stock across 2 purchases in the last 90 days, the largest of them $93.8K.
The average purchase added about 17% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating LEGN in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 9, 2027Earnings report
$LEGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LEGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LEGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LEGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LEGN Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New LEGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LEGN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LEGN
| IBBiShares Biotechnology ETF | $19.38M |
| IEMGiShares Core MSCI Emerging Markets ETF | $12.74M |
| PBEInvesco Biotechnology & Genome ETF | $9.01M |
| CANCTema Oncology ETF | $3.19M |
| GNOMGlobal X - Genomics & Biotechnology ETF | $2.91M |
| EEMiShares MSCI Emerging Markets ETF | $2.83M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LEGN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings showed revenue growth and profitability swing, but RBC cut price target despite maintaining outperform; concerns over decelerating CARVYKTI demand offset positive sales growth.
Recent Insider Activity
Insider Score Trend Over Time
+88.7 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.20% |
| PBE | Invesco Biotechnology & Genome ETF | 2.46% |
| MEMS | Matthews Emerging Markets Discovery Active ETF MEMS | 2.38% |
| GNOM | Global X - Genomics & Biotechnology ETF | 2.22% |
| CHNA | Loncar China BioPharma ETF | 2.06% |
| CANC | Tema Oncology ETF | 1.73% |
| EMSF | Matthews Emerging Markets Sustainable Future Active ETF EMSF | 1.61% |
| MEDI | Harbor Health Care ETF (MEDI) | 1.09% |
| KURE | KraneShares MSCI All China Health Care Index ETF | 0.82% |
| BBP | Virtus Biotech ETF | 0.70% |
| JDOC | JPMorgan Healthcare Leaders ETF | 0.30% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.29% |
Weight is the stock’s share of each fund’s holdings.
